CSPC Pharmaceutical Group (1093) Fundamentals 2026 — P/E 21.3x, Revenue Analysis | SniperIQ
CSPC Pharmaceutical Group (1093) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of HK$95.8B, trading at HK$8.40 on the HKSE. This SniperIQ fundamentals page covers CSPC Pharmaceutical Group's valuation (P/E 21.3x, P/B 2.5x), profitability (net margin 14.9%), revenue (¥25.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CSPC Pharmaceutical Group's market cap?
CSPC Pharmaceutical Group (1093) has a market capitalization of approximately HK$95.8B, trading at HK$8.40 on the HKSE. Market cap moves with the live share price.
What is CSPC Pharmaceutical Group's P/E ratio?
CSPC Pharmaceutical Group's trailing twelve-month P/E ratio is 21.3x, with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CSPC Pharmaceutical Group?
CSPC Pharmaceutical Group runs a net profit margin of 14.9%, a gross margin of 65.6%, and an operating margin of 15.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CSPC Pharmaceutical Group generate?
CSPC Pharmaceutical Group reported revenue of ¥25.3B for fiscal year 2025, with net income of ¥3.8B and earnings per share (EPS) of 0.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does CSPC Pharmaceutical Group pay a dividend?
CSPC Pharmaceutical Group offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is CSPC Pharmaceutical Group financially healthy?
CSPC Pharmaceutical Group carries a debt-to-equity ratio of 0.02x and a current ratio of 2.19x, with a market beta of 0.72. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CSPC Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CSPC Pharmaceutical Group (1093) the key facts are: market cap HK$95.8B, P/E 21.3x, revenue ¥25.3B, 52-week range 6.53-11.63. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track CSPC Pharmaceutical Group's full fundamentals live
Get CSPC Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.